9-ING-41
规格
| Cas Number | 1034895-42-5 |
| 规格或纯度 | Moligand™, ≥98% |
| 级别 | Moligand™ |
| 纯度 | ≥98% |
| 包装 | 100mg 或 50mg 或 10mg 或 5mg 或 25mg |
产品信息
| 品牌 | 阿拉丁 |
| Action Type | 抑制剂 |
| Mechanism Of Action | 糖原合酶激酶-3 beta 抑制剂 |
| 溶解性 | Solubility (25°C) In vitro DMSO: 81 mg/mL (200.32 mM); Water: Insoluble; Ethanol: Insoluble; |
| 简短描述 | GSK-3 抑制剂 |
| 英文简短描述 | GSK-3 Inhibitors |
| 过滤标签 | glycogen synthase kinase 3 beta Inhibitor,GSK-3,Stem Cell/Wnt,PI3K/Akt/mTOR |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | 9-ING-41 是一种具有抗肿瘤活性的糖原合酶激酶-3（GSK-3）强效抑制剂。9-ING-41 通过靶向中心体和与微管结合的 GSK3β，诱导细胞凋亡并使细胞周期停滞在前期。 |
| 英文描述 |
Information 9-ing-41 9-ING-41 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with antitumor activity. 9-ING-41 induces apoptosis and cell cycle arrest at prophase by targeting centrosomes and microtubule-bound GSK3β. Targets GSK-3 In vitro 9-ING-41, a clinically relevant small molecule GSK-3β inhibitor with broad spectrum pre-clinical antitumor activity, suppresses the growth of neuroblastoma cells. 9-ING-41 induces apoptosis and cell cycle arrest at prophase by targeting centrosomes and microtubule-bound GSK3β. In vivo 9-ING-41 has single-agent antitumor activity in a mouse model of MCL. Mouse xenograft studies shows that the combination of clinically relevant doses of CPT-11 and 9-ING-41 lead to greater antitumor effect than is observed with either agent alone. Cell Research(from reference) Cell lines：Neuroblastoma cell lines SK-N-DZ, SK-N-BE Concentrations：0.1 μM–1 μM Incubation Time：48 h |